Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

142. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin 23906445 2014 08 18 2015 05 12 2014 08 18 1463-1326 16 2 2014 Feb Diabetes, obesity & metabolism Diabetes Obes Metab Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. 159-69 10.1111/dom.12189 (...) ) 31.9 kg/m(2) ; body weight 91.5 kg] inadequately controlled on metformin. Patients (N = 182) were randomly assigned 1 : 1 to receive dapagliflozin 10 mg/day or placebo added to open-label metformin for a 24-week double-blind treatment period followed by a 78-week site- and patient-blinded extension period. At week 102, changes from baseline in HbA1c, weight, waist circumference, total body fat mass as measured by dual-energy X-ray absorptiometry (DXA), serum markers of bone turnover

EvidenceUpdates2013

143. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial 23906415 2014 08 18 2015 05 12 2015 06 15 1463-1326 16 2 2014 Feb Diabetes, obesity & metabolism Diabetes Obes Metab Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo (...) -controlled trial. 147-58 10.1111/dom.12188 This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients with type 2 diabetes (T2DM). Patients with HbA1c ≥7 and ≤10% were randomized and treated with once daily empagliflozin 10 mg (n = 165), empagliflozin 25 mg (n = 168) or placebo (n = 165) as add-on to pioglitazone ± metformin for 24 weeks. Endpoints included changes from baseline in HbA1c (primary endpoint), fasting plasma glucose (FPG

EvidenceUpdates2013

144. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia 23906374 2013 11 06 2014 05 22 2013 11 06 1463-1326 15 12 2013 Dec Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. 1154-60 10.1111/dom.12185 To evaluate the effects of the sodium (...) glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12 weeks in patients with type 2 diabetes. This dose-ranging, double-blind, placebo-controlled trial randomized 495 participants with type 2 diabetes inadequately controlled on metformin [haemoglobin A1c (HbA1c) >7 to ≤10%] to receive 1, 5, 10, 25, or 50 mg empagliflozin once daily (QD), or placebo, or open-label sitagliptin (100 mg QD), added to metformin for 12 weeks. The primary endpoint was change in HbA1c from baseline

EvidenceUpdates2013

145. linagliptin/metformin (Jentadueto®)

linagliptin/metformin (Jentadueto®) linagliptin/metformin (Jentadueto®) linagliptin/metformin (Jentadueto®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). linagliptin/metformin (Jentadueto®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All (...) Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No.1113. 2013 Authors' conclusions Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus: as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin

Health Technology Assessment (HTA) Database.2013

146. Does metformin prevent diabetes in at-risk adults?

Does metformin prevent diabetes in at-risk adults? Does metformin prevent diabetes in at-risk adults? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Does metformin prevent diabetes in at-risk adults? View/ Open Date 2013-08 Format Metadata Abstract Metformin therapy reduces the risk of developing diabetes for adults (...) with one or more risk factors for at least 5 years (strength of recommendation [SOR]: A, consistent meta-analyses) and perhaps as long as 10 years (SOR: B, randomized clinical trial [RCT]). Lifestyle modification with diet and exercise is approximately twice as effective as metformin for preventing diabetes, especially in older patients (SOR: B, RCTs). URI Citation Journal of Family Practice, 62(8) 2013: 436-437. Collections hosted by hosted by

Clinical Inquiries2013

147. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes (...) inadequately controlled with metformin. METHODS: We undertook this 52 week, randomised, double-blind, active-controlled, phase 3 non-inferiority trial at 157 centres in 19 countries between Aug 28, 2009, and Dec 21, 2011. Patients aged 18-80 years with type 2 diabetes and glycated haemoglobin A1c (HbA1c) of 7·0-9·5% on stable metformin were randomly assigned (1:1:1) by computer-generated random sequence via an interactive voice or web response system to receive canagliflozin 100 mg or 300 mg

Lancet2013

148. Empagliflozin As Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Empagliflozin As Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial 23963895 2013 10 25 2015 03 20 2016 12 15 1935-5548 36 11 2013 Nov Diabetes care Diabetes Care Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. 3396-404 10.2337/dc12-2673 To investigate the efficacy and tolerability of empagliflozin as add (...) -on to metformin and sulfonylurea in patients with type 2 diabetes. Patients inadequately controlled on metformin and sulfonylurea (HbA1c ≥7 to ≤10%) were randomized and treated with once-daily empagliflozin 10 mg (n = 225), empagliflozin 25 mg (n = 216), or placebo (n = 225) for 24 weeks. The primary end point was change from baseline in HbA1c at week 24. Key secondary end points were changes from baseline in weight and mean daily glucose (MDG) at week 24. At week 24, adjusted mean (SE) changes from baseline

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

149. Metformin use in adolescents

Metformin use in adolescents Metformin use in adolescents Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Metformin use in adolescents View/ Open Date 2013-04 Format Metadata Abstract There are no studies evaluating whether metformin prevents or delays the onset of diabetes in adolescents who are obese. In adults (...) , metformin is as effective as lifestyle interventions in preventing increases in A1C and fasting glucose levels, but it is less effective in preventing or delaying the onset of overt type 2 diabetes. Metformin use reduces body mass index (BMI) for up to six months in adolescents who are obese (Strength of Recommendation [SOR]: C, based on disease-oriented randomized controlled trials [RCTs]) and reduces insulin resistance, the prevalence and severity of steatosis, and nonalcoholic fatty liver disease

Clinical Inquiries2013

150. Linagliptin/metformin (Jentadueto) - type 2 diabetes mellitus

Linagliptin/metformin (Jentadueto) - type 2 diabetes mellitus All Wales Medicines Strategy Group (AWMSG) - linagliptin/metformin (Jentadueto) | | Appraisal information Search and reports linagliptin/metformin (Jentadueto®) Reference No. 1681 Publication date: 31/07/2013 Last review date: 30/08/2016 Appraisal information linagliptin/metformin (Jentadueto®) 2.5 mg/1000 mg film-coated tablet linagliptin/metformin (Jentadueto®) 2.5 mg/850 mg film-coated tablet Company: Boehringer Ingelheim Ltd BNF (...) category: Endocrine system NMG meeting date: 10/04/2013 AWMSG meeting date: 08/05/2013 Submission Type: Limited Submission Status: Recommended Advice No: 1113 Ratification by Welsh Government: 29/07/2013 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus: • as an adjunct to diet and exercise

All Wales Medicines Strategy Group2013

151. [Saxagliptine/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

[Saxagliptine/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Saxagliptin/Metformin – Nutzenbewertung gemäß § 35a SGB V [Saxagliptine/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Saxagliptin/Metformin – Nutzenbewertung gemäß § 35a SGB V [Saxagliptine/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Saxagliptin/Metformin – Nutzenbewertung gemäß § 35a SGB V. [Saxagliptine/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 152

Health Technology Assessment (HTA) Database.2013

152. [Addendum to Commission A12-16 Saxagliptin/metformin]

[Addendum to Commission A12-16 Saxagliptin/metformin] Addendum zum Auftrag A12-16 (Saxagliptin/Metformin) [Addendum to Commission A12-16 Saxagliptin/metformin] Addendum zum Auftrag A12-16 (Saxagliptin/Metformin) [Addendum to Commission A12-16 Saxagliptin/metformin] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Addendum zum (...) Auftrag A12-16 (Saxagliptin/Metformin). [Addendum to Commission A12-16 Saxagliptin/metformin] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 161. 2013 Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Hypoglycemic Agentss; Metformin Language Published German Country of organisation Germany English summary There is no English

Health Technology Assessment (HTA) Database.2013

153. Saxagliptin + metformin (Komboglyze) - adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus

Saxagliptin + metformin (Komboglyze) - adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus

Scottish Medicines Consortium2013

154. Vildagliptin / metformin hydrochloride (Eucreas) - Treatment of type 2 diabetes mellitus

Vildagliptin / metformin hydrochloride (Eucreas) - Treatment of type 2 diabetes mellitus Published 13 May 2013 Statement of Advice vildagliptin/metformin hydrochloride (Eucreas ® ) 50 mg/850 mg and 50 mg/1000 mg film-coated tablets (No: 874/13) Novartis Pharmaceuticals UK Ltd 05 April 2013 ADVICE: in the absence of a submission from the holder of the marketing authorisation vildagliptin/metformin hydrochloride (Eucreas ® ) is not recommended for use within NHS Scotland. Indication under review (...) : Treatment of type 2 diabetes mellitus: • in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea • in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control The holder of the marketing authorisation has not made a submission to SMC

Scottish Medicines Consortium2013

155. Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M) 23536584 2013 08 23 2014 04 21 2017 02 20 1935-5548 36 9 2013 Sep Diabetes care Diabetes Care Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). 2543-50 10.2337/dc12-2006 To examine the efficacy and safety of lixisenatide (20 μg once daily, administered (...) before the morning or evening meal) as add-on therapy in patients with type 2 diabetes insufficiently controlled with metformin alone. This was a 24-week, randomized, double-blind, placebo-controlled study in 680 patients with inadequately controlled type 2 diabetes (HbA1c 7-10% [53-86 mmol/mol]). Patients were randomized to lixisenatide morning (n = 255), lixisenatide evening (n = 255), placebo morning (n = 85), or placebo evening (n = 85) injections. Lixisenatide morning injection significantly

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

156. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus 23039321 2013 01 28 2013 08 02 2013 11 21 1463-1326 15 3 2013 Mar Diabetes, obesity & metabolism Diabetes Obes Metab Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. 252-7 10.1111/dom.12020 The aim of this study is to assess the efficacy and safety of vildagliptin 50 mg bid as add (...) -on therapy to insulin in type 2 diabetes mellitus (T2DM). This is a multicentre, double-blind, placebo-controlled, parallel group, clinical trial in T2DM patients inadequately controlled by stable insulin therapy, with or without metformin. Patients received treatment with vildagliptin 50 mg bid or placebo for 24 weeks. In all, 449 patients were randomized to vildagliptin (n = 228) or placebo (n = 221). After 24 weeks, the difference in adjusted mean change in haemoglobin A1c (HbA1c) between vildagliptin

EvidenceUpdates2013

157. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin

Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin 23020608 2013 01 28 2013 08 02 2013 11 21 1463-1326 15 3 2013 Mar Diabetes, obesity & metabolism Diabetes Obes Metab Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. 246-51 10.1111/dom.12017 We compared metformin with insulin as treatment of gestational diabetes mellitus (GDM). Furthermore (...) , we aimed to characterize metformin-treated patients needing additional insulin to achieve prespecified glucose targets. We conducted a single centre randomized controlled study with non-inferiority design comparing metformin and insulin in the treatment of 217 GDM patients having birth weight as primary outcome variable. There were no significant differences in mean birth weight expressed in grams [+15 (90% confidence interval (CI): -121 to 89)] or SD units [+0.04 (90% CI: -0.27 to 0.18)] between

EvidenceUpdates2013

158. Article The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome : The Diabetes Prevention Program

Article The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome : The Diabetes Prevention Program Article The Effect of Metformin a... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2005 ) Volume: 142 , Issue: 8 , Pages: 611-619 ISSN: 15393704 ISBN: PubMed: Available from or Find this paper at: Abstract BACKGROUND: The metabolic syndrome is a high-risk (...) state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance. OBJECTIVE: To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution. DESIGN: Randomized, controlled clinical trial. SETTING: Research and community-based centers. PARTICIPANTS: Participants had impaired

Annals of Internal Medicine2013

159. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis Liu SC, Tu YK (...) anti-diabetic agents added to metformin in patients with type 2 diabetes. Searching PubMed and Cochrane Central Register of Controlled Trials were searched up to December 2011 for English language publications. Search terms were reported. Reference lists of relevant articles were manually examined. Study selection Eligible for inclusion were randomised controlled trials (RCTs) that compared anti-diabetic drugs plus metformin versus placebo or other different class anti-diabetic agents in adults (18

DARE.2013

160. Linagliptin+metformin (Jentadueto) - Treatment of adult patients with type 2 diabetes mellitus

Linagliptin+metformin (Jentadueto) - Treatment of adult patients with type 2 diabetes mellitus Published 11 February 2013 Product Update linagliptin 2.5mg plus metformin 850mg and linagliptin 2.5mg plus metformin 1000mg film-coated tablets (Jentadueto®) (No: 841/13) Boehringer Ingelheim 11 January 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission linagliptin plus metformin tablets (Jentadueto®) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of adult patients with type 2 diabetes mellitus: ? as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin

Scottish Medicines Consortium2013